Market Access
Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.
Developing a Balanced Scorecard for a Core Laboratory
April 28 by Dr. Susan ShelbyThe balanced scorecard was first developed as a way for companies and organizations to more accurately measure their own performances. Today, these scorecards have evolved into vital tools for biophar...
Global Pharmaceutical Serialisation and Track & Trace Open House 2016
April 20 by Pharma IQIn the combat against counterfeit drugs, more than 40 markets – those of which including the EU, US, South Korea, Brazil and China, are deploying pharmaceutical track and trace laws. According to indu...
Global Pharmaceutical Serialisation and Track & Trace Open House 2016 - On Demand
April 20 by Chanice HenryAs the pharma industry advances towards a state of airtight track and trace compliance, Pharma IQ’s Global Pharmaceutical Serialisation and Track & Trace Open House provided a platform for key sta...
The Commercialization Checklist: A Guide To Success For Emerging Pharma
April 12 by Paula BoultbeeThere are questions virtually everyone in our industry asks when the topic of commercialization inevitably comes up: What is new in molecule commercialization? How do I beat my closest competitor? Whe...
“Future-proofing” Serialization Solutions: The Importance of Strong Level 3 Capabilities
April 12 by Pharmaceuticals & Biotechnology EditorThe complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a...
Q1- The Highlights
April 12 by Pharmaceuticals & Biotechnology EditorThe first quarter of 2016 hosted plenty of activity from the pharma and cold chain industries. This was seen in the form of patent challenges, landmark agreements, extreme market reactions as well as...
Tips for your Serialisation Strategy
April 08 by Andrew LoveSerialisation legislation will require new capabilities to be implemented across many different functions of a typical company.The most obvious include:• Regulatory and legislative management and...
Top Performing Pharmaceuticals Over The Last 5 Years
April 05 by Pharmaceuticals & Biotechnology EditorAs the industry awaits the results for 2015, Pharma IQ takes a look at which pharmaceutical products emerge at the front of the pack on the global healthcare industry. We collated analysis provided by...
Korea’s Global Clinical Trial Magnetism
March 22 by George Clinical RepresentativeThe rising presence of clinical trials (CT) in the Asia-Pacific region is predominantly driven by the East Asian region which includes China, Japan, Korea, Taiwan and Hong Kong. Over the past decade,...
The Translation of Next Generation Therapeutics
March 22 by Tony HitchcockWhen we look at the current trends with what we can refer to as “next generation therapeutics”, whether it be ADCs or cell and gene therapy products, one trend is very clear, products are becoming inc...
Drugs Pricing in France - Balancing Innovation vs Cost Containment: The New Agreement between the Government and the Pharma industry
March 15 by Dr Steven BradshawOn January 11th 2016, the Comité Economique des Produits de Santé (CEPS - Economic Committee for Health Products) signed on the behalf of the French Government a new agreement, the Accord cadre, with...
Pharma & Biotech’s Merger Fever: The Highlights
March 08 by Chanice HenryIn 2015, the pharma and biotech industry was diagnosed with what was coined as merger fever. Industry analysts state that the first half of 2015 soared past 2014’s grand total of $162 billion, with th...